Monosubstituted Maltosyl Cyclodextrins for the Potential Treatment of NPC
Niemann-Pick type C is a sever lysosomal storage disease, commonly refereed as ‘children’s Alzheimer’. There is no cure for it
A forum for researchers, students and applicants in the field of cyclodextrin technology
Niemann-Pick type C is a sever lysosomal storage disease, commonly refereed as ‘children’s Alzheimer’. There is no cure for it
Recent reviews emphasized the role of membrane lipids in the infectivity mechanism of SARS-COV-2. Cholesterol-rich parts of cell membranes serve
Home-based intravenous infusions of Trappsol® Cyclo™ for up to one year show improvement in disease features or disease stabilization Cyclo
Strategic drug repurposing in combination with rapid testing of established molecular targets could provide a pause in disease progression and
Cyclo Therapeutics, Inc., a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)
Cyclo Therapeutics, Inc. a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)
Cyclo Therapeutics, Inc. formerly CTD Holdings, Inc., a biotechnology company that develops cyclodextrin-based products for the treatment of disease, announced
CTD Holdings, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical
In the recent two weeks, Cyclolab had the pleasure to welcome two prominent pioneers of cyclodextrin research, Prof. Loftsson from
A paper has just come out in Macromolecular Rapid Communications highlighting the potential benefits of cyclodextrin-based macromolecular systems as cholesterol-mopping